Biologic Drugs

Apr 06, 2018
By Pharmaceutical Technology Editors
Boehringer Ingelheim and OSE Immunotherapeutics have entered a global immuno-oncology partnership to develop a checkpoint inhibitor for treating advanced solid tumors.
Apr 05, 2018
By Pharmaceutical Technology Editors
Fujifilm acquires cell culture media companies Irvine Scientific Sales Company and IS Japan.
Apr 05, 2018
By Pharmaceutical Technology Editors
The European approval marks the first approval for a biosimilar in that region resulting from the companies’ joint portfolio.
Apr 05, 2018
By Pharmaceutical Technology Editors
The companies have created Syna Therapeutics, a joint venture that will develop biosimilars and new molecules.
Apr 03, 2018
By Pharmaceutical Technology Editors
Pfizer transfers CAR-T assets to Allogene Therapeutics under a new alliance to further develop immuno-oncology therapeutics.
Apr 03, 2018
By Pharmaceutical Technology Editors
The agency has accepted AstraZeneca’s biologics license application for an investigational leukemia drug candidate and granted it priority review.
Apr 02, 2018
Pharmaceutical Technology
Researchers at MIT have discovered a new set of compounds that do not elicit a foreign body response when implanted. These biomaterials permit the development of a new category of treatment with the ability to deliver therapeutics either at a constant rate or under programmable conditions by using implantable cells as protein factories.
Apr 02, 2018
Pharmaceutical Technology
The high viscosity of highly concentrated monoclonal antibody formulations not only presents processing and storage difficulties, but also formulation and delivery challenges.
Apr 02, 2018
Pharmaceutical Technology
Access to multiple analytical techniques is essential for fully characterizing complex protein formulations.
Mar 29, 2018
By Pharmaceutical Technology Editors
EMA has recommended approval of the biosimilar for the same indications as Roche’s Herceptin (trastuzumab).
native1_300x100
lorem ipsum